Aim This single-centre randomized, double-blind, placebo-controlled clinical trial assessed the effect of a preoperative, single, oral dose of prednisolone on postoperative pain and postoperative analgesic intake in patients with symptomatic, irreversible pulpitis in mandibular molars. Methodology Four hundred participants, randomly assigned to two equal groups, received either 40 mg prednisolone or placebo tablets 30 min before singlevisit root canal treatment. Patients recorded their pain level 6, 12 and 24 h after treatment on a 100-mm visual analogue scale. All patients received a sham capsule to take if needed as a postoperative analgesic, and, if the pain persisted, an analgesic was prescribed. The relative risk reduction and 95% confidence intervals (CI) were estimated for binary data. Mann-Whitney U-test was used to compare postoperative pain intensity between groups. Results The relative risk reduction in pain incidence was 20.31% (95% CI: 12.03%, 27.82%) at 6 h, 23.39% (95% CI: 14.75%, 31.16%) at 12 h and 28.85% (95% CI: 18.08%, 38.20%) at 24 h. Prednisolone had significantly less post-obturation pain intensity compared to placebo at 6, 12 and 24 h (P < 0.001). The relative risk reduction in sham-capsule intake was 54% (95% CI: 38%, 66%) and of analgesic intake was 55% (95% CI: 3%, 79%). No adverse effects were recorded. Conclusion Preoperative oral administration of a single dose of 40 mg prednisolone was beneficial to control short-term post-obturation pain after singlevisit root canal treatment in patients with symptomatic irreversible pulpitis reducing pain incidence after 24 h by approximately 30% and postoperative analgesic intake by approximately 55%.
Introduction
Postoperative pain, which commences a few hours or days after treatment, is always an unpleasant experience for both patients and clinicians (Wang et al. 2010) . Thus, its prevention and management are of prime importance. Previous studies have reported that the prevalence of post-endodontic pain is 40% at 24 h (Ng et al. 2004 , Pak & White 2011 . Pre-treatment, intratreatment and post-treatment factors contribute to postoperative pain (Ng et al. 2004 , Arias et al. 2013 . Pre-treatment factors include age, gender, tooth type and medical status (Ng et al. 2004) . Intratreatment factors include the number of visits, irrigant or intracanal medication used, root canal instrumentation technique, sealer type, overextension or extrusion of infected debris, whilst hyperocclusion of temporary filling represents a post-treatment factor (Seltzer & Naidorf 1985 , Arias et al. 2013 .
Drugs with different mechanisms of action have been used for the management of post-endodontic pain including non-narcotic analgesics comprising nonsteroidal anti-inflammatory medicines (NSAIDs) and acetaminophen, opioids and steroids. Glucocorticoids are the most common steroids used in endodontics (Marshall 2002) . They inhibit the production of multiple cells and factors essential for the occurrence of the inflammatory process where they decrease vasoactive and chemoattractive factors and reduce the extravasation of leucocytes to the areas of tissue injury (Marshall 2002 , Hargreaves & Abbott 2005 .
Several synthetic glucocorticoids have been used in endodontics. Some studies have assessed the effect of orally administrated glucocorticoids on the control of post-endodontic pain after root canal instrumentation (Glassman et al. 1989 , Pochapski et al. 2009 , Jalalzadeh et al. 2010 . However, only one study evaluated the effect of a pre-emptive, single-dose, orally administrated prednisolone on postoperative pain with a recommendation for performing other clinical trials with more control of study variables to limit bias and provide more reliable results (Jalalzadeh et al. 2010) .
The results of clinical trials evaluating the benefits of preoperative orally administrated prednisolone are still inconclusive. Thus, the aim of this study was to assess the effect of a single-dose, orally administrated, 40 mg prednisolone on postoperative pain after singlevisit root canal treatment of teeth with symptomatic irreversible pulpitis. A single-centre, randomized, parallel, two-arm, double-blind, clinical trial with an allocation ratio of 1 : 1 study design was utilized.
Materials and methods

Study design and sampling
This study is a single-centre, randomized, controlled, parallel-group, double-blind clinical trial with 1-day follow-up (Trial Registration: Clinical trials.gov Ref. NCT02819648). The research protocol and the informed consent format were approved by the Institutional Review Board of the Ethics Committee of the School of Dentistry, Cairo University, Egypt. All included patients signed an informed consent after the explanation of the involved procedures and the possible risks. The patients were recruited from the outpatient clinic of the Department of Endodontics from 2012 to 2014.
Eligibility criteria
The inclusion criteria comprised systemically healthy patients, aged between 18 and 35 years, having mandibular molars with symptomatic irreversible pulpitis, radiographically normal periapical area and no pain on biting or percussion.
The exclusion criteria comprised: pregnant patients, patients with sensitivity or adverse reactions to any of the medications or materials used in this study, those who had used an analgesic during the preceding 6 h before the treatment, those with unrestorable teeth or teeth with severe periodontal disease. Patients with active sites of pathosis in the area of injection were, also, excluded.
The diagnosis of symptomatic irreversible pulpitis was made from the chief complaint as well as the clinical examination. Preoperative pain was the main diagnostic sign of symptomatic irreversible pulpitis. Pulp sensitivity was confirmed by a positive response to an electric pulp test (Denjoy DY310 Dental Pulp Tester, Denjoy, Henan, China) and a prolonged exaggerated response (>10 s) with moderate-to-severe pain to a cold test, using ethyl chloride spray (Walter Ritter GmbH, Hamburg, Germany). Final confirmation of pulp vitality was achieved during the access cavity preparation.
Sample size calculation
The sample size calculation, based on an alpha error = 0.05 and a power of 0.95, indicated that a total sample of 320, 160 in each group, would be required to detect a minimal clinically important difference of 20% in the incidence of postoperative pain between the two groups. The expected incidence of postoperative pain in the control group was approximately 60% (Parirokh et al. 2012) . With the consideration of 25% dropout rate, 400 patients were required. Sample size calculation was achieved using PS: Power and Sample Size Calculation software Version 3.1.2 (Vanderbilt University, Nashville, TN, USA).
Randomization
The independent Centre for Evidence-Based Dentistry, Cairo University, performed sequence generation and allocation concealment. For randomization, a permuted-block method was performed with ten blocks, 40 patients per block, one operator per block. The random sequence generation for each block was generated using (random.org). Each block was randomly divided into two groups: group A (prednisolone), where patients received 40 mg prednisolone (two tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France); and group B (control), where patients received two placebo tablets. All patients received the assigned premedication 30 min before the administration of local anaesthesia administration by a nurse not involved in the study.
For allocation concealment, two tablets of each medication were placed in sequentially numbered, opaque, sealed containers according to the random sequence generated for allocation concealment. On allocation, the number on the container was written on the patient's chart to allow decoding during data management. Both the participants and the operators were unaware of the assigned group throughout the duration of the study. There was no chance for patients to meet each other along the course of the trial to ensure patient blinding.
For calibration of operators, fourteen postgraduate students received a pre-study training for 3 weeks on technical procedures of single-visit root canal treatment. Further, five supervisors from the staff members of the Department of Endodontics evaluated their clinical performance. Ten postgraduate students who were graded more than 80% and were eligible to participate in the clinical treatment of patients were included.
Clinical procedures
Each patient was anaesthetized using 1.8 mL of Mepecaine-L local anaesthesia, composed of 20 mg mL À1 Mepivacaine hydrochloride U.S.P. and 0.06 mg mL À1 Levonordefrin hydrochloride (Alexandria Co. for Pharmaceuticals, Alexandria, Egypt). If any patient felt pain during access or instrumentation, an additional cartridge was administrated. After access cavity preparation, the tooth was isolated with a rubber dam and working length was determined using an apex locator then confirmed radiographically to be 1 mm short of the radiographic apex. Root canal instrumentation was carried out using a rotary system (Revo-S TM , Micro Mega â , Besanc ßon, France) according to the manufacturer's instructions. Root canals were instrumented initially using a size 15 K-file (Mani, Mani Inc. Utsunomiya, Tochigi, Japan). The operator prepared the canals to a minimum of size 30, .06 taper according to the cleaning and shaping needs. The canals were thoroughly irrigated using 3 mL 2.6% sodium hypochlorite using a 27-needle gauge between every two successive instruments. A chelating cream (MD-Chelcream. Meta Biomed Co. Ltd., Chungbuk, Korea) was used as a lubricant. The final flush was performed using saline. The canals were then dried and treated using a modified single-cone technique using matched-size guttapercha points (MM-GP Points, Micro Mega â ) and a resin-based sealer (Adseal, Meta Biomed Co. Ltd.). The operator placed a cotton pellet in the pulp chamber and restored the access cavity with the temporary filling (MD-Temp, Meta Biomed Co. Ltd.).
Pain measurement
Each patient received a pain diary with a visual analogue scale (VAS) (Williamson & Hoggart 2005) for three time-points: 6, 12 and 24 h after the root canal treatment. The VAS consisted of a 100-mm line anchored by two extremes 'no pain' and 'worst pain', and one investigator (SW) translated it to the native language. After being trained to use the VAS, each patient was asked to make a mark on the line that represented their level of pain at 6, 12 and 24 h after the root canal treatment. Patients were contacted by their operator at each time-point to check on the patient and as a reminder. Following root canal treatment, each patient was dismissed with a sham capsule, as an analgesic, and instructed to take it only in the presence of pain. If pain persisted after taking the sham, the patient was instructed to contact the operator who would then prescribe an analgesic (Diclofenac Potassium 50 mg, Novartis Pharma SAE, Pathion Inc., Ontario, Canada). Patients were asked to record in the pain diary whether they took the sham and whether they needed an analgesic for confirmation. An independent assessor (MR) recorded adverse effects, for example nausea, dizziness, headache, nervousness, drowsiness, insomnia or other.
Patients were instructed to return the pain diary after 24 h. One assessor (SW), blinded to the patient treatment, was responsible for measuring the pain score from the zero anchor to the patient's mark using a millimetre scale. Baseline data, including data on gender, age and tooth type and adverse effects, were obtained from the diagnostic and procedural charts of all patients by one data manager (AE). All the data were collected and tabulated in MS Excel sheets (Microsoft Corporation, Redmond, WA, USA).
Primary and secondary outcomes
The primary outcome was the incidence of postoperative pain at the three time-points: 6, 12 and 24 h. The incidence of postoperative pain was measured as a binary outcome; 'No pain' if the patient scored 'zero' and 'Pain' if the patient scored otherwise on the visual analogue scale. The secondary outcomes included the following: postoperative pain intensity at 6, 12 and 24 h, the incidence of a sham capsule intake during the 24 h, and incidence of analgesic consumption during the 24 h. Postoperative pain intensity was measured as a continuous outcome driven from the visual analogue scale, whilst the incidence of sham capsule intake and analgesic consumption were measured as binary outcomes.
Statistical analysis
The relative risk reduction (RRR) and the numberneeded-to-treat (NNT) and their 95% confidence intervals (CI) were used to represent the risk of pain incidence. For pain intensity, Kolmogorov-Smirnov and Shapiro-Wilk tests confirmed a non-normal distribution (P < 0.05); thus, the nonparametric Mann-Whitney Utest was used to compare between groups. For baseline and adverse effects data, the chi-square test was used to compare categorical data, and the Student's t-test was used to compare numerical data between groups. An intention-to-treat approach was used as analysis population. An expert statistician (ID) performed statistical analysis using the Statistical Package for Social Science (SPSS, IBM Corporation, New York, USA) version 18 with a significance level of P ≤ 0.05.
Results
Of the 670 patients assessed for eligibility, 400 were included in the study. Only two patients of the 400 were lost to follow-up with 398 patients (prednisolone group = 198; control group = 200) being included in the analysis (Fig. 1) ; 259 were women and 141 men. The mean age was 29.45 AE 3.7 years in the prednisolone group and 28.97 AE 3.61 years in the control group. There was no significant difference for mean age (P = 0.164), gender distribution (P = 0.123) or tooth type (P = 0.56) between the two groups (Table 1) .
After 6 h, 142 of 198 patients felt pain in the prednisolone group, whilst 180 of 200 patients in the control group felt pain. The relative risk reduction (RRR) was 20.31% (95% confidence interval [CI]: 12.03%, 27.82%) compared to the control. The number-needed-to-treat (NNT) was five (95% CI: 4, 9); that is, it was necessary to premedicate five patients with prednisolone for one extra patient to benefit compared to the control.
After 12 h, 135 of 198 patients felt pain in the prednisolone group, whilst 178 of 200 patients in the control group felt pain. The RRR was 23.39% (95% CI: 14.75%, 31.16%) compared to the control. The NNT was five (95% CI: 4, 8) where again it was necessary to premedicate five patients with prednisolone for one extra patient to benefit compared to the control.
After 24 h, 112 of 198 patients felt pain in the prednisolone group, whilst 159 of 200 patients in the control group felt pain. The RRR was 28.85% (95% CI: 18.08%, 38.20%) compared to the control. The NNT was four (95% CI: 3, 7) where it was necessary to premedicate four patients with prednisolone for one extra patient to benefit compared to the control.
The prednisolone group had significantly lower pain intensity compared to the placebo group at 6, 12 and 24 h (P < 0.000 for each; Table 2 ). There was a significant decrease in postoperative pain over the postoperative duration of 24 h. For the prednisolone group, the pain intensity was significantly less at 12 h compared to 6 h (P = 0.001) and at 24 h compared to 12 h (P = 0.000). For the control group, also, pain intensity was significantly less at 12 h compared to 6 h (P = 0.000) and at 24 h compared to 12 h (P = 0.000).
The incidence of sham uptake was significantly less in the prednisolone group compared to the control group (P = 0.000; Table 3 ). The RRR of sham intake was 54% (95% CI: 38%, 66%) and the NNT was 4 (95% CI: 3, 6).
The incidence of analgesic intake was significantly less in the prednisolone group compared to the control group (P = 0.036; Table 3 ). The RRR was 55% (95% CI: 3%, 79%) and the NNT 18 (95% CI: 9, 352).
Twelve endodontic files fractured in the prednisolone group and 16 in the control group (P = 0.449). The patients receiving interventions recorded no adverse effects.
Discussion
The aim of this clinical trial was to evaluate the effect of the preoperative, oral administration of a single dose of prednisolone compared to a placebo on the incidence of postoperative pain in patients with symptomatic irreversible pulpitis who received root canal treatment in one visit. Few studies have assessed the effect of orally administrated glucocorticoids on post-treatment pain (Krasner & Jackson 1986 , Glassman et al. 1989 . One study on prednisolone (Jalalzadeh et al. 2010 ) was published with relatively high exclusions/dropout rate, and the imbalance in the distribution of symptomatic and asymptomatic cases suggested a risk of bias in the results. Thus, the need for another study to confirm the results and facilitate clinical decisionmaking was necessary.
Single-centre randomized controlled trials allow adequately powered studies with large sample sizes to be performed more easily than multicentre studies. Also, they are logistically easier, cheaper, simpler in data collection and do not consume time in negotiating the study protocol (Bellomo et al. 2009 ). The use of block randomization ensured that each operator treated an equal number of patients in the prednisolone and control groups. Although the inclusion of ten operators in the trial could impose operator bias, the difference between them simulated the real life situation.
The participants were relatively young with an overall mean age of 29.2 years. It should be noted that younger patients anticipate and experience higher pain levels compared to older ones (Watkins et al. 2002) .
A 100-mm visual analogue scale was used to evaluate pain intensity; this scale was used in previous studies that analysed pain after root canal treatment (Gopikrishna & Parameswaran 2003 , Attar et al. 2008 , Arslan et al. 2011 ). The VAS is more sensitive to small changes than simple descriptive ordinal scales. Amongst the limitations of the VAS are that it must be administered on paper or electronically and photocopying of the scale should be performed with caution to avoid changes in length (Williamson & Hoggart 2005) .
The choice of patient-relevant outcome measures is important (Torabinejad & Bahjri 2005) ; the high feasibility of patient-relevant outcomes might be indicated by high response rates achieved with their use (Shah et al. 2011) . In the present study, postoperative pain, along with sham and medication intake, as patient-reported outcomes were used. A high response rate of 99.5% and a lower rate of loss to follow-up were achieved due to the short study duration.
Prednisolone reduced the risk of postoperative pain incidence by about 30% at 24 h. The numberneeded-to-treat (NNT) was four for prednisolone at 24 h which indicates the number of patients that must take the drug to observe 'no pain' on one more person than in the control group. The smaller the NNT, the more effective the intervention is.
Patients who received prednisolone reported significantly less pain compared to the placebo group over the first 24 h following single-visit conventional root canal treatment for symptomatic irreversible pulpitis. Such results (Table 2 ) are consistent, entirely or partially, with previous investigations (Pochapski et al. 2009 ). Jalalzadeh et al. (2010) found that a preoperative, single, oral dose of 30 mg of prednisolone substantially reduced pain in teeth with vital and nonvital pulps treated in one visit. In another study, the preoperative, oral administration of a single dose of 4 mg dexamethasone reduced pain at 4 and 12 h only but not 24 or 48 h (Pochapski et al. 2009) . The difference between the two studies is probably attributed to the difference in the pulpal disease involved where cases with asymptomatic irreversible pulpitis were selected. Preoperative pain is considered a prognostic factor for postoperative pain (Arias et al. 2013) . As for the sham or analgesic intake following single-visit root canal treatment, prednisolone provided significantly less need for rescue medication, whether sham or analgesic. The reduction in the relative risk of the need for rescue medication with prednisolone was more than half (54% for the need for sham and 55% for the need of analgesic, respectively) compared to that required for the control group. The discrepancy in the risk reduction values of postoperative pain and need for rescue medication may, somewhat indirectly, give a rough estimation of the patients who could have suffered mild pain that did not require medication intake.
Rescue medication was administered if the pain has not diminished after about an hour. This protocol is reasonable because not all patients taking the drug will have adequate pain relief (Moore et al. 2011) . In this trial, a sham capsule was used initially as a rescue medication not to mask the initial postoperative pain intensity followed by analgesic intake if the patient's symptoms persisted. Patients who took it would be reported but not eliminated from the trial as an 'intention-to-treat analysis' was used in this study. Thus, the potential for bias in the assessment of treatment effects was minimized, and the study power was maintained (Lachin 2000) .
A preoperative, single, oral dose of anti-inflammatory drugs can modulate the release of inflammatory mediators and reduce the occurrence of side effects compared with repeated doses during the postoperative period (Pochapski et al. 2009 ). Pretreatment analgesia before root canal treatment may decrease the establishment of central sensitization whereby spinal neurons increase their responsiveness to peripheral nociceptive input (Attar et al. 2008) , which could amplify postoperative pain (Kissin 2000) . Preoperative administration, as well, would be of particular significance with glucocorticoids which may require time for their effects to be mediated (Marshall 2002) .
In this study, no adverse effects were detected which negates a previous study where dizziness was detected in 10% of patients after periapical infiltration injection of dexamethasone to control postoperative endodontic pain (Shantiaee et al. 2012) . Although some concerns may exist as to the harmful effects of the use of glucocorticoids, for example increasing the susceptibility to infection, a single dose has been reported to have no detrimental effects (Liesinger et al. 1993 , Alexander & Throndson 2000 , Mehrvarzfar et al. 2008 .
Amongst the limitations of this study was the lack of baseline preoperative pain data. However, with the large sample size in this study, any probable imbalance would have been minimized. Further, the use of block randomization in a sample size of 400 patients with an allocation ratio of 1 : 1 is expected to eliminate mean imbalances between groups.
Unlike multicentre randomized controlled trials, the pool of patients in single-centre randomized controlled trial originates from one place. Thus, external validity when applying these results to different population would be compromised. Further, the relatively narrow age range included in this study, 18-35 years, could diminish the generalizability of the results to patients older than 35 years.
Conclusions
Preoperative oral administration of a single dose of 40 mg prednisolone was beneficial for the control of postoperative pain up to 24 h after single-visit root canal treatment in patients with symptomatic irreversible pulpitis. Thus, the incidence of postoperative pain, the postoperative pain level and the need for postoperative analgesic intake decreased. The relatively easy, noninvasive route of administration together with the safety of the intervention, pose little if any, possibility of adverse effects could result in a favourable risk-benefit balance.
